Parabilis CMO reports initial stock option holdings
Parabilis Medicines, Inc. Chief Medical Officer Mohammed Fawzi Benzaghou reported his initial beneficial ownership on Form 3, showing two stock option awards for common stock.
Rhea-AI Filing Summary
Parabilis Medicines, Inc. Chief Medical Officer Mohammed Fawzi Benzaghou reported his initial beneficial ownership on Form 3, showing two stock option awards for common stock. One option covers 243,680 underlying shares at an exercise price of $3.14 per share, expiring on February 17, 2036.
The second option covers 357,398 underlying shares at an exercise price of $2.42 per share, expiring on September 10, 2035. Vesting is time-based: one grant vests 25% on September 2, 2026 with the rest monthly over 36 months, and the other vests in 48 equal monthly installments starting February 9, 2026, subject to continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Benzaghou Mohammed Fawzi
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 601,078 contracts (Direct)
Footnotes (2)
- F1. 25% of the shares subject to this option shall vest and become exercisable on September 2, 2026 with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
- F2. The shares subject to this option shall vest and become exercisable in forty-eight (48) equal monthly installments commencing from February 9, 2026, subject to the Reporting Person's continued service on each such vesting date.
Key Figures
Underlying shares (grant 1): 243,680 shares
Exercise price (grant 1): $3.14/share
Underlying shares (grant 2): 357,398 shares
+4 more
7 metrics
Underlying shares (grant 1)
243,680 shares
Stock option on common stock, exercise price $3.14
Exercise price (grant 1)
$3.14/share
Stock option, expires February 17, 2036
Underlying shares (grant 2)
357,398 shares
Stock option on common stock, exercise price $2.42
Exercise price (grant 2)
$2.42/share
Stock option, expires September 10, 2035
Total underlying shares
601,078 shares
Combined underlying common shares from two option grants
Vesting start (grant 1)
September 2, 2026
25% cliff vest, remainder monthly over 36 months
Vesting start (grant 2)
February 9, 2026
Vests in 48 equal monthly installments
Key Terms
Stock Option (right to buy), underlying security, exercise price, vesting, +1 more
5 terms
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
underlying security financial
"underlying_security_title: Common Stock; underlying_security_shares listed"
exercise price financial
"conversion_or_exercise_price: 3.1400 and 2.4200"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"shares subject to this option shall vest and become exercisable"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 3 regulatory
"INSIDER FILING DATA (Form 3)"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Parabilis Medicines (PBLS) disclose in this Form 3 filing?
Parabilis Medicines (PBLS) discloses Chief Medical Officer Mohammed Fawzi Benzaghou’s initial beneficial ownership of two stock option awards. The filing details option sizes, exercise prices, expiration dates, and time-based vesting schedules tied to his continued service with the company.
What are the exercise prices of the Parabilis Medicines (PBLS) stock options?
The reported Parabilis Medicines (PBLS) stock options have exercise prices of $3.14 and $2.42 per share. These prices represent the cost per share to acquire PBLS common stock once the respective options have vested and are exercisable, subject to continued service conditions.
When do the Parabilis Medicines (PBLS) CMO’s stock options expire?
The CMO’s PBLS stock options expire on February 17, 2036 and September 10, 2035. These expiration dates define the last days on which vested options can be exercised to purchase Parabilis Medicines common stock before they lapse.
How do the Parabilis Medicines (PBLS) stock options vest for the CMO?
One PBLS option vests 25% on September 2, 2026, with the remaining 75% vesting in 36 equal monthly installments. The other vests in 48 equal monthly installments starting February 9, 2026. Vesting is contingent on the CMO’s continued service on each vesting date.
Does this Parabilis Medicines (PBLS) Form 3 show any stock purchases or sales?
This PBLS Form 3 does not show stock purchases or sales; it reports existing derivative holdings. It lists the Chief Medical Officer’s stock option positions, including share amounts, exercise prices, expiration dates, and vesting schedules, rather than recording open-market trading activity.
AI-generated analysis. How Rhea-AI works. Not financial advice.
